David Meeker Quote David Meeker Quote Dr. Shoemaker quote Dr. Shoemaker quote IMCIVREE packaging IMCIVREE packaging with vial ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

Rhythm Pharmaceuticals’ setmelanotide receives US FDA approval to treat patients living with acquired hypothalamic obesity: Boston Saturday, March 21, 2026, 18:00 Hrs [IST] Rhyt ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfuncti ...

Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...

Rhythm Pharmaceuticals received Food and Drug Administration approval for an expanded indication for setmelanotide, its treatment for acquired hypothalamic obesity. Acquired hypothalamic obesity is a ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

Rhythm Pharmaceuticals (NASDAQ:RYTM) shares rose 11% Friday morning following FDA approval of IMCIVREE (setmelanotide) for ...

Transdermal estradiol for locally advanced prostate cancer matched luteinizing hormone-releasing hormone (LHRH) agonists as ...

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s ...

Future treatment resistance to focal epilepsy therapy was significantly more likely in individuals who reported suicidal ...